Marksans Pharma Ltd.

₹184.1

-8 (-4.2%)

MARKSANS Share Price

Pharmaceuticals & Biotechnology

As on April 28, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 8,353 Cr

P/E Ratio21.92

Dividend Yield0.43 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	187.85	Bearish
10-DMA	183.12	Bullish
20-DMA	176.39	Bullish
50-DMA	174.44	Bullish
100-DMA	176.8	Bullish
200-DMA	185.66	Bearish

Historical Performance

1 Year

-15.3%

3 Years

127.8%

5 Years

151.2%

10 Years

302%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Net Sales	26,228	21,774	18,521	14,908	13,762
Total Expenditure	20,942	17,188	15,128	12,320	10,366
Other Income	704	504	593	419	67
Operating Profit	5,990	5,090	3,986	3,007	3,463
Interest	117	112	91	84	80
Depreciation	834	743	519	448	362
Profit Before Tax	5,040	4,235	3,377	2,475	3,022
Consolidated Net Profit	3,806	3,137	2,663	1,846	2,359
Adjusted EPS	8	7	6	5	6

Compounded Sales Growth

10 Years:26.9

5 Years:18.3

3 Years:12

TTM:3.8

Compounded Profit Growth

10 Years:28.3

5 Years:26.6

3 Years:15.6

TTM:3.9

Stock Price CAGR

10 Years:14.9

5 Years:20.8

3 Years:31.6

TTM:-16.1

Return on Equity

10 Years:1.9

5 Years:5.8

3 Years:5.9

last year:8.4

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2025	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Share Capital	453	453	453	409	409
Total Reserves	24,216	20,197	16,998	10,682	8,456
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	2,729	2,052	843	571	237
Other Current Liabilities	1,172	706	422	968	797
Short Term Borrowings	231	291	416	413	187
Total Liabilities	32,396	26,810	21,904	16,601	12,280
Capital Work in Progress	90	54	72	7	56
Long Term Loans & Advances	263	329	189	42	42
Currents Investments	7	270	5	4	3
Short Term Loans and Advances	812	598	355	318	10
Total Current Assets	22,041	18,625	16,753	12,251	9,028
Total Assets	32,396	26,810	21,904	16,601	12,280
Adjusted Book Value	54	46	39	27	22

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a moderate PE of 21.92, suggesting fair valuation relative to earnings.
Over the last three years, the stock delivered a strong 3-year price CAGR of 31.3%, indicating sustained price appreciation.
The stock carries a beta of 1.0, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹5990 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹26228 million, indicating a large and established business.

Investment Calculator

Investment Amount:

₹

Investment Amount: ₹ 1000000

Current Value: ₹ 839412.7

No. of Shares: 4560 (Approx)

Performance:-16.1%

P/L: ₹-160587.3

NIFTY Performance: -1.4%

1 day Top Gainers